NR3C1 and prostate cancer: Although therapeutic approaches to develop inhibitors against AR are widely used in the clinic, AR signaling can also be initiated in prostate cancer cells from the bypass via glucocorticoid receptor (GR) signaling, thus making prostate cancer cells resistant to AR inhibitors (46).